252 related articles for article (PubMed ID: 22460799)
1. TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements.
Tan AY; Riley TR; Coady T; Bussemaker HJ; Manley JL
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6030-5. PubMed ID: 22460799
[TBL] [Abstract][Full Text] [Related]
2. Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein.
Yang S; Warraich ST; Nicholson GA; Blair IP
Int J Biochem Cell Biol; 2010 Sep; 42(9):1408-11. PubMed ID: 20541619
[TBL] [Abstract][Full Text] [Related]
3. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
[TBL] [Abstract][Full Text] [Related]
4. Arginine methylation of translocated in liposarcoma (TLS) inhibits its binding to long noncoding RNA, abrogating TLS-mediated repression of CBP/p300 activity.
Cui W; Yoneda R; Ueda N; Kurokawa R
J Biol Chem; 2018 Jul; 293(28):10937-10948. PubMed ID: 29784880
[TBL] [Abstract][Full Text] [Related]
5. RNA sequence and length contribute to RNA-induced conformational change of TLS/FUS.
Hamad N; Mashima T; Yamaoki Y; Kondo K; Yoneda R; Oyoshi T; Kurokawa R; Nagata T; Katahira M
Sci Rep; 2020 Feb; 10(1):2629. PubMed ID: 32060318
[TBL] [Abstract][Full Text] [Related]
6. Promoter-associated long noncoding RNAs repress transcription through a RNA binding protein TLS.
Kurokawa R
Adv Exp Med Biol; 2011; 722():196-208. PubMed ID: 21915790
[TBL] [Abstract][Full Text] [Related]
7. m
Yoneda R; Ueda N; Kurokawa R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681673
[TBL] [Abstract][Full Text] [Related]
8. ALS mutations in TLS/FUS disrupt target gene expression.
Coady TH; Manley JL
Genes Dev; 2015 Aug; 29(16):1696-706. PubMed ID: 26251528
[TBL] [Abstract][Full Text] [Related]
9. Identification of DNA binding specificity for TLS.
Takahama K; Arai S; Kurokawa R; Oyoshi T
Nucleic Acids Symp Ser (Oxf); 2009; (53):247-8. PubMed ID: 19749353
[TBL] [Abstract][Full Text] [Related]
10. FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment.
Morlando M; Dini Modigliani S; Torrelli G; Rosa A; Di Carlo V; Caffarelli E; Bozzoni I
EMBO J; 2012 Dec; 31(24):4502-10. PubMed ID: 23232809
[TBL] [Abstract][Full Text] [Related]
11. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells.
Rodriguez R; Rubio R; Gutierrez-Aranda I; Melen GJ; Elosua C; García-Castro J; Menendez P
Stem Cells; 2011 Feb; 29(2):179-92. PubMed ID: 21732477
[TBL] [Abstract][Full Text] [Related]
12. TAR DNA binding protein-43 and fused in sarcoma/translocated in liposarcoma protein in two neurodegenerative diseases.
Wang XN; Cui LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Jun; 34(3):286-92. PubMed ID: 22776664
[TBL] [Abstract][Full Text] [Related]
13. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.
Kuroda M; Ishida T; Horiuchi H; Kida N; Uozaki H; Takeuchi H; Tsuji K; Imamura T; Mori S; Machinami R
Am J Pathol; 1995 Nov; 147(5):1221-7. PubMed ID: 7485386
[TBL] [Abstract][Full Text] [Related]
14. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.
Zou J; Ichikawa H; Blackburn ML; Hu HM; Zielinska-Kwiatkowska A; Mei Q; Roth GJ; Chansky HA; Yang L
Mol Cell Biol; 2005 Jul; 25(14):6235-46. PubMed ID: 15988032
[TBL] [Abstract][Full Text] [Related]
16. TLS and PRMT1 synergistically coactivate transcription at the survivin promoter through TLS arginine methylation.
Du K; Arai S; Kawamura T; Matsushita A; Kurokawa R
Biochem Biophys Res Commun; 2011 Jan; 404(4):991-6. PubMed ID: 21187067
[TBL] [Abstract][Full Text] [Related]
17. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.
Haile S; Lal A; Myung JK; Sadar MD
PLoS One; 2011; 6(9):e24197. PubMed ID: 21909421
[TBL] [Abstract][Full Text] [Related]
18. The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS.
Yamaguchi A; Kitajo K
PLoS One; 2012; 7(11):e49267. PubMed ID: 23152885
[TBL] [Abstract][Full Text] [Related]
19. The binding specificity of Translocated in LipoSarcoma/FUsed in Sarcoma with lncRNA transcribed from the promoter region of cyclin D1.
Yoneda R; Suzuki S; Mashima T; Kondo K; Nagata T; Katahira M; Kurokawa R
Cell Biosci; 2016; 6():4. PubMed ID: 26816614
[TBL] [Abstract][Full Text] [Related]
20. The RNA-binding protein FUS/TLS undergoes calcium-mediated nuclear egress during excitotoxic stress and is required for
Tischbein M; Baron DM; Lin YC; Gall KV; Landers JE; Fallini C; Bosco DA
J Biol Chem; 2019 Jun; 294(26):10194-10210. PubMed ID: 31092554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
